Cardax, Inc. (CDXI)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Jun 13, 2025
Cardax Company Description
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress.
It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity.
The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration.
Cardax, Inc. is based in Honolulu, Hawaii.
Contact Details
Address: 2800 Woodlawn Drive Honolulu, Delaware 96822 United States | |
| Phone | 808 457 1400 |
| Website | cardaxpharma.com |
Stock Details
| Ticker Symbol | CDXI |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US14141D2018 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David G. Watumull | Chairman and Chief Executive Officer |
| David M. Watumull | Chief Operating Officer and Chief Financial Officer |
| Gilbert Shin | Vice President of Retail Sales and Marketing |